These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 19323787

  • 1. The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study.
    de Bruijne EL, Gils A, Guimarães AH, Dippel DW, Deckers JW, van den Meiracker AH, Poldermans D, Rijken DC, Declerck PJ, de Maat MP, Leebeek FW.
    J Thromb Haemost; 2009 Jun; 7(6):919-27. PubMed ID: 19323787
    [Abstract] [Full Text] [Related]

  • 2. Haplotypes of TAFI gene and the risk of cerebral venous thrombosis--a case-control study.
    Orikaza CM, Morelli VM, Matos MF, Lourenço DM.
    Thromb Res; 2014 Jan; 133(1):120-4. PubMed ID: 24252537
    [Abstract] [Full Text] [Related]

  • 3. A new functional assay of thrombin activatable fibrinolysis inhibitor.
    Guimarães AH, Bertina RM, Rijken DC.
    J Thromb Haemost; 2005 Jun; 3(6):1284-92. PubMed ID: 15946219
    [Abstract] [Full Text] [Related]

  • 4. Thrombin-activatable fibrinolysis inhibitor in human abdominal aortic aneurysm disease.
    Bridge KI, Bollen L, Zhong J, Hesketh M, Macrae FL, Johnson A, Philippou H, Scott DJ, Gils A, Ariёns RAS.
    J Thromb Haemost; 2017 Nov; 15(11):2218-2225. PubMed ID: 28834317
    [Abstract] [Full Text] [Related]

  • 5. A functional single nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease.
    Kremer Hovinga JA, Franco RF, Zago MA, Ten Cate H, Westendorp RG, Reitsma PH.
    J Thromb Haemost; 2004 Jan; 2(1):54-7. PubMed ID: 14717966
    [Abstract] [Full Text] [Related]

  • 6. Impact of genetic polymorphisms in thrombin activatable fibrinolysis inhibitor (TAFI) on venous thrombosis disease: A meta-analysis.
    Qian K, Xu J, Wan H, Fu F, Lu J, Lin Z, Liu Z, Liu H.
    Gene; 2015 Sep 15; 569(2):173-81. PubMed ID: 26071134
    [Abstract] [Full Text] [Related]

  • 7. TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study.
    Morange PE, Tregouet DA, Frere C, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Cambien F, Tiret L, Juhan-Vague I, Prime Study Group.
    J Thromb Haemost; 2005 Jul 15; 3(7):1503-10. PubMed ID: 15978108
    [Abstract] [Full Text] [Related]

  • 8. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke.
    Leebeek FW, Goor MP, Guimaraes AH, Brouwers GJ, Maat MP, Dippel DW, Rijken DC.
    J Thromb Haemost; 2005 Oct 15; 3(10):2211-8. PubMed ID: 16092924
    [Abstract] [Full Text] [Related]

  • 9. Thrombin-activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children.
    Emonts M, de Bruijne EL, Guimarães AH, Declerck PJ, Leebeek FW, de Maat MP, Rijken DC, Hazelzet JA, Gils A.
    J Thromb Haemost; 2008 Feb 15; 6(2):268-76. PubMed ID: 18021301
    [Abstract] [Full Text] [Related]

  • 10. Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis.
    de Bruijne EL, Darwish Murad S, de Maat MP, Tanck MW, Haagsma EB, van Hoek B, Rosendaal FR, Janssen HL, Leebeek FW, Liver and Thrombosis Study Group.
    Thromb Haemost; 2007 Feb 15; 97(2):181-5. PubMed ID: 17264944
    [Abstract] [Full Text] [Related]

  • 11. Plasma thrombin-activatable fibrinolysis inhibitor and the 1040C/T polymorphism are risk factors for diabetic kidney disease in Chinese patients with type 2 diabetes.
    Huang Q, Feng D, Pan L, Wang H, Wu Y, Zhong B, Gong J, Lin H, Fei X.
    PeerJ; 2023 Feb 15; 11():e16352. PubMed ID: 38025709
    [Abstract] [Full Text] [Related]

  • 12. Plasma thrombin-activatable fibrinolysis inhibitor levels and Thr325Ile polymorphism as a risk marker of myocardial infarction in Egyptian patients.
    Kamal HM, Ahmed AS, Fawzy MS, Mohamed FA, Elbaz AA.
    Acta Cardiol; 2011 Aug 15; 66(4):483-8. PubMed ID: 21894805
    [Abstract] [Full Text] [Related]

  • 13. Thrombin activatable fibrinolysis inhibitor plasma levels and TAFI Thr325Ile genetic polymorphism in a cohort of Egyptian sickle cell disease patients and impact on disease severity.
    Hamdy M, Shaheen IA, Khallaf M, Selim YMM.
    Pediatr Blood Cancer; 2024 Jun 15; 71(6):e30959. PubMed ID: 38520679
    [Abstract] [Full Text] [Related]

  • 14. Genetic variations in the thrombin-activatable fibrinolysis inhibitor gene and risk of cardiovascular disease: a systematic review and meta-analysis.
    Shi J, Zhi P, Chen J, Wu P, Tan S.
    Thromb Res; 2014 Sep 15; 134(3):610-6. PubMed ID: 25042727
    [Abstract] [Full Text] [Related]

  • 15. Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity.
    Zhou X, Weeks SD, Ameloot P, Callewaert N, Strelkov SV, Declerck PJ.
    J Thromb Haemost; 2016 Aug 15; 14(8):1629-38. PubMed ID: 27279497
    [Abstract] [Full Text] [Related]

  • 16. Thrombin-activatable fibrinolysis inhibitor Thr325Ile polymorphism and plasma level in breast cancer: A pilot study.
    Fawzy MS, Mohammed EA, Ahmed AS, Fakhr-Eldeen A.
    Meta Gene; 2015 Jun 15; 4():73-84. PubMed ID: 25893174
    [Abstract] [Full Text] [Related]

  • 17. Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis.
    Wang X, Smith PL, Hsu MY, Tamasi JA, Bird E, Schumacher WA.
    J Thromb Thrombolysis; 2007 Feb 15; 23(1):41-9. PubMed ID: 17111204
    [Abstract] [Full Text] [Related]

  • 18. Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris.
    Brouwers GJ, Leebeek FW, Tanck MW, Wouter Jukema J, Kluft C, de Maat MP.
    Thromb Haemost; 2003 Jul 15; 90(1):92-100. PubMed ID: 12876631
    [Abstract] [Full Text] [Related]

  • 19. [Study on the association of thrombin activatable fibrinolysis inhibitor and the Thr325Ile and Thr147Ala polymorphisms of its encoding gene CPB2 in patients with coronary heart disease].
    Xu CW, Wang LL, Wu XB, Zhao JJ, Du YM, Jiang CY.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug 15; 25(4):438-42. PubMed ID: 18683146
    [Abstract] [Full Text] [Related]

  • 20. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
    Zorio E, Castelló R, Falcó C, España F, Osa A, Almenar L, Aznar J, Estellés A.
    Br J Haematol; 2003 Sep 15; 122(6):958-65. PubMed ID: 12956767
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.